Targeting the Untargetable: [ 161 Tb]Tb-FAP-2286 in Young-Onset Refractory Cholangiocarcinoma

Indian Journal of Nuclear Medicine 2026 Open access

Read full text
Authors: Swagat Dash, Vindhya Malasani, Rakhee Vatsa, Majid Assadi, Habibollah Dadgar, Hossein Arabi, Amit Verma, Dinesh Pendharkar
DOI: 10.25259/ijnm_31_2026
Cited by: 1
References: 13

Abstract

Paediatric and adolescent cholangiocarcinoma (CCC) is extremely rare, and an advanced-stage diagnosis precludes surgical intervention as a primary treatment. Therefore, early diagnosis and precise staging are critical for improving patient outcomes. A pronounced desmoplastic reaction is the hallmark of cholangiocarcinoma, positioning FAPI as a promising theragnostic approach for patients unresponsive to conventional therapies. We present a case of young-onset refractory cholangiocarcinoma, refractory to multiple treatment lines, administered [ 161 Tb]Tb-FAP-2286, exhibiting a partial response.

Fields of Study & Subjects

Peptidase Inhibition and Analysis Cholangiocarcinoma and Gallbladder Cancer Studies Connective tissue disorders research

Publication details

Journal / source
Indian Journal of Nuclear Medicine
Publisher
Scientific Scholar
Volume
41
Pages
237–240
Publication date
10 April 2026
Language
EN